Advances in Hypertension Management: Intensive Control and New Medications

Hypertension, or high blood pressure, affects approximately 1.28 billion adults aged 30 to 79 globally. If left untreated, it can lead to serious health complications, including heart disease, stroke, and kidney disease. Traditionally, medical guidelines have recommended maintaining systolic blood pressure around 140 mmHg. However, recent studies suggest that more intensive control, targeting levels below 120 or 130 mmHg, may significantly reduce the risk of major cardiovascular events.

Intensive Blood Pressure Control Linked to Lower Risk of Heart Attack and Stroke'High blood pressure is never healthy -- even in old age'AstraZeneca’s Baxdrostat Shows Promise in Treating Resistant High Blood PressurePeople with treatment-resistant hypertension may benefit from a new medicationNew drug baxdrostat proves effective in lowering resistant hypertension in Phase III trial

A comprehensive analysis published in *The Lancet* examined data from about 80,000 participants across six clinical trials in China, Canada, and the United States. This study found that individuals who underwent intensive blood pressure control experienced fewer heart attacks, strokes, and cardiovascular-related deaths compared to those treated with standard goals. Despite the benefits, researchers noted that intensive control could lead to side effects such as dizziness and kidney issues, emphasizing the need for individualized treatment approaches.

Intensive Blood Pressure Control Linked to Lower Risk of Heart Attack and Stroke

Professor Kang Si-hyuck from Seoul National University Bundang Hospital highlighted the outdated belief that moderately high blood pressure is necessary for heart function. He referenced the SPRINT Trial, which demonstrated a 25% reduction in cardiovascular events when targeting blood pressure below 120 mmHg. This trial led to changes in hypertension guidelines in the U.S., Europe, and Korea.

'High blood pressure is never healthy -- even in old age'

In addition to lifestyle changes and existing medications, a new drug called baxdrostat has shown promise for patients with treatment-resistant hypertension. In a Phase III clinical trial involving nearly 800 participants, baxdrostat significantly reduced systolic blood pressure by approximately 9-10 mmHg more than a placebo. This reduction is linked to a lower risk of heart attack, stroke, and kidney disease. The drug works by inhibiting aldosterone production, a hormone that contributes to high blood pressure through increased sodium and water retention.

People with treatment-resistant hypertension may benefit from a new medicationNew drug baxdrostat proves effective in lowering resistant hypertension in Phase III trialAstraZeneca’s Baxdrostat Shows Promise in Treating Resistant High Blood Pressure'High blood pressure is never healthy -- even in old age'Intensive Blood Pressure Control Linked to Lower Risk of Heart Attack and Stroke

Dr. Bryan Williams, the principal investigator of the baxdrostat trial, noted that the findings could potentially benefit up to half a billion people worldwide, particularly those struggling with uncontrolled hypertension. The trial results were presented at the European Society of Cardiology Congress 2025 and published in the *New England Journal of Medicine*.

New drug baxdrostat proves effective in lowering resistant hypertension in Phase III trial

Despite the promising findings, some skepticism exists regarding the motivations behind hypertension research. Critics have raised concerns about potential pharmaceutical influence on studies. However, Professor Kang clarified that the SPRINT study was funded by the U.S. National Institutes of Health, not pharmaceutical companies, countering claims of bias.

'High blood pressure is never healthy -- even in old age'

The recent advancements in hypertension management underscore the importance of tailored treatment strategies. As guidelines evolve, healthcare providers are encouraged to consider individual patient circumstances when determining blood pressure targets and treatment plans. The introduction of baxdrostat may enhance treatment options for those with resistant hypertension, marking a significant step forward in managing this prevalent health issue.

New drug baxdrostat proves effective in lowering resistant hypertension in Phase III trial

• “Achieving a nearly 10 mmHg reduction in systolic blood pressure with baxdrostat is exciting, as this level of reduction is linked to substantially lower risk of heart attack, stroke, heart failure, and kidney disease.” — Professor Bryan Williams, Principal Investigator

New drug baxdrostat proves effective in lowering resistant hypertension in Phase III trial

• “The idea that blood pressure needs to be high is truly an outdated notion,” — Professor Kang Si-hyuck, Seoul National University Bundang Hospital

'High blood pressure is never healthy -- even in old age'

• “Williams elaborated on the implications of the findings: “These results represent a significant advancement in treatment and enhance our understanding of the underlying causes of challenging hypertension.” — Professor Bryan Williams, Principal Investigator

New drug baxdrostat proves effective in lowering resistant hypertension in Phase III trial

The ongoing research and evolving guidelines in hypertension management reflect a commitment to improving patient outcomes and addressing a critical global health issue.

New drug baxdrostat proves effective in lowering resistant hypertension in Phase III trial